文献速递产科母胎医学

硝苯地平与拉贝洛尔口服治疗轻度慢性高血压的妊娠结局比较

Pregnancy Outcomes of Nifedipine Compared With Labetalol for Oral Treatment of Mild Chronic Hypertension.
PubMed 文献 · Obstet Gynecol · 2024-05-23

本研究为CHAP试验的计划二次分析,比较拉贝洛尔、硝苯地平与标准护理对轻度慢性高血压孕妇结局的影响。结果显示拉贝洛尔和硝苯地平较标准护理降低主要复合结局风险,但两药之间无显著差异。

要点

  • 拉贝洛尔与硝苯地平组主要复合结局风险均低于标准护理组,两药间无显著差异。
  • 拉贝洛尔与硝苯地平组小于胎龄儿及严重不良事件无显著差异。
  • 药物选择基于临床医生或患者偏好,非随机分组。

核心结论

  • 基于拉贝洛尔或硝苯地平治疗妊娠期慢性高血压,预设的母儿结局无显著差异。

研究设计与样本

  • CHAP试验的计划二次分析,开放标签、多中心、随机试验,比较抗高血压治疗与标准护理(不治疗除非出现严重高血压)。
  • 纳入孕20周前血压140-159/90-104 mm Hg的轻度慢性高血压且单胎妊娠的孕妇。
  • 分析2292例参与者,其中拉贝洛尔组720例(31.4%),硝苯地平组417例(18.2%),无治疗组1155例(50.4%)。
  • 入组时平均孕龄10.5±3.7周;47.5%为非西班牙裔黑人;44.5%使用阿司匹林。
  • 活性治疗组内药物分配非随机,基于临床医生或患者偏好。

主要发现

  • 主要结局(叠加子痫前期伴严重特征、35周前早产、胎盘早剥或胎儿/新生儿死亡)发生率:拉贝洛尔组217例(30.1%),硝苯地平组130例(31.2%),标准护理组427例(37.0%)。
  • 拉贝洛尔组 vs 标准护理组主要结局调整RR 0.82(95%CI 0.72-0.94);硝苯地平组 vs 标准护理组调整RR 0.84(95%CI 0.71-0.99)。
  • 拉贝洛尔组 vs 硝苯地平组主要结局调整RR 0.98(95%CI 0.82-1.18),无显著差异。
  • 拉贝洛尔组与硝苯地平组小于胎龄儿及严重不良事件无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 活性治疗组内药物分配非随机,基于临床医生或患者偏好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate maternal and neonatal outcomes by type of antihypertensive used in participants of the CHAP (Chronic Hypertension in Pregnancy) trial. METHODS: We conducted a planned secondary analysis of CHAP, an open-label, multicenter, randomized trial of antihypertensive treatment compared with standard care (no treatment unless severe hypertension developed) in pregnant patients with mild chronic hypertension (blood pressure 140-159/90-104 mm Hg before 20 weeks of gestation) and singleton pregnancies. We performed three comparisons based on medications prescribed at enrollment: labetalol compared with standard care, nifedipine compared with standard care, and labetalol compared with nifedipine. Although active compared with standard care groups were randomized, medication assignment within the active treatment group was not random but based on clinician or patient preference. The primary outcome was the occurrence of superimposed preeclampsia with severe features, preterm birth before 35 weeks of gestation, placental abruption, or fetal or neonatal death. The key secondary outcome was small for gestational age (SGA) neonates. We also compared medication adverse effects between groups. Relative risks (RRs) and 95% CIs were estimated with log binomial regression to adjust for confounding. RESULTS: Of 2,292 participants analyzed, 720 (31.4%) received labetalol, 417 (18.2%) received nifedipine, and 1,155 (50.4%) received no treatment. The mean gestational age at enrollment was 10.5±3.7 weeks; nearly half of participants (47.5%) identified as non-Hispanic Black; and 44.5% used aspirin. The primary outcome occurred in 217 (30.1%), 130 (31.2%), and 427 (37.0%) in the labetalol, nifedipine, and standard care groups, respectively. Risk of the primary outcome was lower among those receiving treatment (labetalol use vs standard adjusted RR 0.82, 95% CI, 0.72-0.94; nifedipine use vs standard adjusted RR 0.84, 95% CI, 0.71-0.99), but there was no significant difference in risk when labetalol was compared with nifedipine (adjusted RR 0.98, 95% CI, 0.82-1.18). There were no significant differences in SGA or serious adverse events between participants receiving labetalol and those receiving nifedipine. CONCLUSION: No significant differences in predetermined maternal or neonatal outcomes were detected on the basis of the use of labetalol or nifedipine for treatment of chronic hypertension in pregnancy. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02299414.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Sanusi AA, Leach J, Boggess K, et al. Pregnancy Outcomes of Nifedipine Compared With Labetalol for Oral Treatment of Mild Chronic Hypertension. Obstet Gynecol. 2024. PMID: 38949541. doi:10.1097/AOG.0000000000005613

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。